Dexamethasone for Prolonged Sensory and Motor Block
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to compare the effect of a single dose of 8 mg of intravenous dexamethasone versus placebo on the duration of sensory and motor block after spinal anesthesia with chloroprocaine.
Who Is on the Research Team?
Stephan Williams, MD, PhD
Principal Investigator
Santé Québec - CHUM
Are You a Good Fit for This Trial?
This trial is for adults who are receiving spinal anesthesia with chloroprocaine. People cannot join if they have conditions or allergies that would make dexamethasone unsafe, but specific inclusion and exclusion details were not provided.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Dexamethasone
Trial Overview
The study compares a single dose of intravenous dexamethasone (8 mg) to a placebo (normal saline) to see how each affects the length of numbness and muscle weakness after spinal anesthesia with chloroprocaine.
How Is the Trial Designed?
2
Treatment groups
Active Control
Placebo Group
During the performance of spinal anesthesia using isobaric 1% chloroprocaine 50 mg, an intravenous infusion of dexamethasone 8 mg (2 ml) will be initiated. The study drug will be administered intravenously over one minute. The study drug will be prepared by an independent assistant.
During the performance of spinal anesthesia using isobaric 1% chloroprocaine 50 mg, an intravenous infusion of 2 ml of Normal Saline will be initiated. The normal saline will be administered intravenously over one minute. The study drug will be prepared by an independent assistant.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Centre hospitalier de l'Université de Montréal (CHUM)
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.